BRCAcare®

DNA-based Next Generation Sequencing (NGS) technologies provide high sensitivity and accuracy for the detection of BRCA and other gene mutations.

Tests Available:

- **BRCA1/2: Comprehensive BRCA Analysis**
- **BRCA1/2: Ashkenazi Jewish 3-site Mutation Analysis**
- **BRCA1 & BRCA 2: Specific Site Analysis**
- **Testing for Hereditary Breast & Ovarian Cancer Syndrome (HBOC)**
  - **Breast Cancer High Risk Extended Panel Plus: 14 genes** (*BRCA1, BRCA2, CDH1, PTEN, TP53, STK11, ATM, CHEK2, PALB2, BARD1, BRIP1, MUTYH, RAD51C, RAD51D*)
  - **Breast Cancer High Risk Extended Panel (No BRCA1, BRCA2): 12 genes** (*CDH1, PTEN, TP53, STK11, ATM, CHEK2, PALB2, BARD1, BRIP1, MUTYH, RAD51C, RAD51D*)
  - ***BRCA1/2*: Ashkenazi Jewish 3-site Mutation Analysis** (Reflex to Breast Cancer High Risk Extended Panel Plus if negative)
- **Testing for Lynch Syndrome genes:**
  - **Comprehensive Hereditary Breast and Gynecologic Cancer Panel: 19 genes** analyzed by Gene Sequencing and/or Deletion/Duplication Analysis (*BRCA1, BRCA2, ATM, BARD1, BRIP1, CDH1, CHEK2, MUTYH, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53, EPCAM, MLH1, MSH2, MSH6, PMS2*).

Now Available

Targets genes of elevated risk for the development of breast, ovarian, and endometrial uterine cancer.

Advantages:

- Non-invasive
- Ease of collection
- Rapid turnaround time
- High sensitivity and specificity
- Genetic counseling can be arranged
- Patient friendly pricing

UNLOCK YOUR BRCA CODE®

Upd: 4/2017

Medical Diagnostic Laboratories L.L.C.

A MEMBER OF GENESIS BIOTECHNOLOGY GROUP®

www.mdlab.com • 877.269.0090

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

MEDICAL DIAGNOSTIC LABORATORIES L.L.C.
2439 KUSER ROAD, HAMILTON, NJ 08690-3303
TL: 609-570-1000, FX: 609-570-1050, TF: 877-269-0090
www.mdlab.com

Preliminary

MDL#: 6522137 **Test Results** **Physician Copy**

Patient Information: **SSN:** XXX-XX-1111 **DOB:** 1/1/1987 (Age: 29)

MRS.DOE, JANE M
56 LIBERTY DRIVE
ABC
DAYTON, NJ 08810

Home: (732) 555-6666 **Patient ID:** TEST123

Ordering Physician/Lab: **NPI:** 2121212121

JOHN DOE, MD
202 ANY STREET
DAYTON, NJ 08810

Tel: (609) 570-1005
Fax: (609) 570-1017

Genetic Counselor Information:



Specimen Type:	Mouthwash
Date Collection:	2/9/2016
Date Processed:	2/10/2016
Date Reported:	

BRCAcare™ 1235: Breast Cancer High Risk Extended Panel Plus: 14 genes

Interpretation Summary:

POSITIVE FOR A LIKELY PATHOGENIC MUTATION

Test Performed	Gene Transcript	Variant	Zygosity	Location	Disease	Inheritance	Parental Origin	Reference	Classification
BRCA1 Sequencing								-	NO ANOMALIES DETECTED
BRCA1 Deletion / Duplication Analysis								-	NO ANOMALIES DETECTED
BRCA2 Sequencing								-	NO ANOMALIES DETECTED
BRCA2 Deletion / Duplication Analysis								-	NO ANOMALIES DETECTED
CDH1 Sequencing	NM_004360.3	c.-285C>A (Non protein-coding)	Heterozygous	Exon5	Cancer (Breast, HDGC Gastric)	Autosomal dominant	Unknown	1-2	LIKELY PATHOGENIC
CHEK2 Sequencing	NM_007194.3	c.1461+1897A>G	Heterozygous	Exon17	Cancer (Breast, Prostate, other)	Autosomal dominant	Unknown	-	VARIANT OF UNCERTAIN SIGNIFICANCE
ATM,BARD1,BRIP1,MUTYH,PALB2,PTEN,RAD51C,RAD51D,STK11,TP53 Sequencing									NO ANOMALIES DETECTED

The following Likely Benign variant was also detected:

Gene	Gene Transcript	Variant	Zygosity	Location	Disease	Inheritance	Parental Origin	Ref.
BARD1	NM_000465.2	c.1518_1519delTGinsCA (p.Val507Met)	Heterozygous	Exon6	Cancer (Breast, Ovarian)	Autosomal dominant	Unknown	-

Comprehensive Interpretation:

View: M

Mail:	Yes	Overnight
	All	Yes

Fax:	Yes	*Manual*
	All	No

Medical Director, Dante A. Ragasa, MD.

BR

MDL#: 6522137
5/31/2016
Preliminary